Price movement over the last 24 hours
Abeona Therapeutics Inc vs Energy Select Sector SPDR Fund — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Energy Select Sector SPDR Fund trades at $55.66. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Energy Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ABEO | XLE | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $62.57 |
52-Week Low | $4.17 | $42.12 |
Enterprise Value | $228.22M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
XLE trades at $53.13, down 0.17% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF has gained 21% year-to-date, ranking among top-performing sector SPDRs according to ETF Trends on July 2, 2026. Recent news highlights oil price volatility and geopolitical developments affecting energy sector performance, while a dividend of $0.38 is scheduled for June 2026.
Outlook remains mixed with technical weakness offset by strong YTD performance. Investment opportunity exists for investors seeking energy sector exposure amid ongoing oil market volatility, though risks include geopolitical tensions and potential Federal Reserve rate hikes that could pressure the sector. The neutral oscillator reading suggests potential for near-term stabilization.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →